Close Menu

NanoString

NanoString has launched the nCounter Single Cell Assay, a single-cell gene expression application for its nCounter digital detection and counting system.

NanoString Technologies this week launched an application for single-cell gene-expression profiling.

After establishing a new diagnostics unit in May, NanoString Technologies is planning to launch its flagship Breast Cancer Intrinsic Subtyping Assay in European markets with CE marking by year end and in the following 12 months file a 510(k) application with US regulators.

Dale Levitzke has been appointed vice president of global sales for life sciences at NanoString Technologies. Levitzke joins the company from Illumina, where he was senior director and global sales manager for the company's PCR division.

Brynn Levy has been elected president of the Cancer Cytogenomics Microarray Consortium. Levy, who is director of clinical cytogenetics at Columbia University Medical Center, will take the reins of the organization from current president Anwar Iqbal next year.

Dale Levitzke has been appointed to vice president of global sales for life sciences at NanoString Technologies.

Kip Miller has been elected to the board of directors at Firefly BioWorks.

Michael Rhodes has left Life Technologies to join NanoString Technologies. At NanoString, Rhodes will be the director of collaboration and applications development and focus on digital gene expression technologies.

NEW YORK (GenomeWeb News) – Pacific Biosciences has appointed Jonas Korlach to chief scientific officer, a position previously held by Eric Schadt, who will remain a key scientific advisor to the company.

Pacific Biosciences has appointed Jonas Korlach to chief scientific officer, a position previously held by Eric Schadt. Schadt will remain a key scientific advisor to the company.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.